NasdaqCM · Biotechnology

Cue Biopharma (CUE)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+379.6%

$115.00 average target

$23.98-0.63 (-2.6%)Latest market snapshot · Yahoo Finance

Market cap$174.2M

Cash$17.4M

Quarterly burn$10.9M

Pipeline assets5

Short float9.1%

Clinical portfolio

Cue Biopharma Drug Pipeline

Showing 1 of 5

Asset	Indication	Stage	Milestone	Signals ?
CUE-221 (Anti-IgE Antibody)	Chronic Spontaneous Urticaria	Phase 2	Sep 30, 2026	—

Continue with BioPharma ProUnlock 4 additional programs and complete development details.

Unlock Pro

Upcoming milestones

CUE Catalyst Timeline

1 currently tracked

Sep 30, 2026

CUE-221 (Anti-IgE Antibody)

Phase 2

Chronic Spontaneous Urticaria

Data readout

Event details

Company profile

About Cue Biopharma

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.